Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Scrub typhus showdown: which antibiotic works best when resistance is rising?

NCT ID NCT03083197

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study tests three antibiotic regimens for scrub typhus, a bacterial infection spread by mites. Researchers compare 7 days of doxycycline, 3 days of doxycycline, and 3 days of azithromycin in 177 hospitalized patients aged 15 and older. The goal is to see which treatment clears fever fastest and prevents relapse, especially in areas where drug resistance is a concern.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
doxycycline and azithromycin
What this could lead to
If successful, this could identify the most effective antibiotic regimen for scrub typhus, potentially reducing treatment failures and relapse in regions with drug resistance.
What could go wrong
This is a relatively small Phase 4 trial (177 participants) in specific regions, so results may not apply everywhere. Antibiotic resistance patterns vary, and the open-label design could introduce bias.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 177 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2017

Expected to finish

Oct 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

15 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥ 15 years old * Hospitalization with acute undifferentiated fever (temperature \> 37.5°C, tympanic) ≤14 days or patients admitted to hospital with a history of fever ≤ 14 days who subsequently develop fever within 24 hours of admission * Clinically suspected scrub typhus: defined as acute undifferentiated fever with no clear focus of infection and negative malaria blood smear and/or negative malaria RDT. Patients may have one, none, or a combination of other clinical findings such as eschar, rash, lymphadenopathy, headache, myalgia, cough, nausea and abdominal discomfort. * A positive scrub typhus RDT (Scrub Typhus IgM RDT, InBios International, Seattle, WA, USA) and/or positive PCR-based detection of O. tsutsugamushi DNA from the admission blood sample * Written informed consent and/or, written informed assent as required * Able to take oral medication Exclusion Criteria: * Known hypersensitivity to tetracycline, doxycycline or azithromycin * Administration of doxycycline, azithromycin, chloramphenicol, rifampicin, or tetracycline during the preceding 7 days * Pregnancy or breast-feeding * Patients with myasthenia gravis or systemic lupus erythematosus * Patients with an established infection (diagnostic test required) e.g. acute malaria, dengue, leptospirosis, typhoid, Japanese encephalitis etc. * Current TB or TB treatment in ≤ 6 months (contain active antibiotics against Orientia spp.) * Current HAART use for HIV, long term use of immunosuppressants (e.g. steroids, chemotherapy, TNF-inhibitors and related agents) * Patients with severe disease whom the clinical team feel their condition necessitates the need for additional scrub typhus treatment beyond the allocated antibiotic treatment assigned at randomization (e.g. IV chloramphenicol and/or PO/NG rifampicin)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Scrub typhus are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Chiangrai Prachanukroh Hospital

    Chiang Rai, Thailand

  • Mae Chan District Hospital

    Chiang Rai, Thailand

  • Mae Fah Luang District Hospital

    Chiang Rai, Thailand

  • Mae Suai District Hospital

    Chiang Rai, Thailand

  • Shoklo-Malaria Research Unit (SMRU)

    Mae Sot, Changwat Tak, Thailand

More trials for these conditions

Other studies related to the condition(s) this trial covers.